ILOF and Bluepharma Partner to Deploy AI-Powered Optomics for Accelerated Drug Development

ILOF and Bluepharma have announced a strategic collaboration to deploy ILOF’s AI-powered Optomics platform to accelerate drug development and advance personalised medicine. The partnership aims to integrate artificial intelligence with optical data analysis to improve patient stratification, optimize clinical trials, and enhance decision-making across the drug development lifecycle.

Advancing Precision Through AI-Driven Optomics

The collaboration will leverage ILOF’s proprietary Optomics technology, which uses advanced optical signatures and machine learning to identify disease biomarkers. By enabling faster and more accurate patient selection, the platform is expected to reduce clinical trial timelines, lower development costs, and increase the probability of regulatory success.

Strengthening Portugal’s Innovation Ecosystem

The alliance also reinforces Portugal’s growing position in biotech innovation, combining Bluepharma’s pharmaceutical expertise with ILOF’s AI capabilities. Together, the companies aim to create scalable, data-driven solutions that support more efficient R&D models and accelerate the transition toward truly personalised therapeutic strategies.